Nayan Desai, MD
Interventional Cardiology · Bismarck, NDNPI 1316368236
Payments from drug & device makers
Across 720 payments — averaging $575.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$88K
- Actelion Pharmaceuticals US, Inc.$81K
- Alnylam Pharmaceuticals Inc.$43K
- Edwards Lifesciences$42K
- Johnson & Johnson$40K
- Boehringer Ingelheim$29K
- plus $91K from 31 others
What the payments were for
- Consulting fees$73,13018%
- Speaking & faculty fees$248,81360%
- Grants$50,00012%
- Travel & lodging$28,3987%
- Food & beverage$11,9913%
- Education$3790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $88,200 |
| Actelion Pharmaceuticals US, Inc. | 132 | $80,971 |
| Alnylam Pharmaceuticals Inc. | 37 | $43,329 |
| Edwards Lifesciences | 74 | $42,483 |
| Johnson & Johnson | 45 | $39,601 |
| Boehringer Ingelheim | 36 | $29,328 |
| Lilly USA, LLC | 22 | $20,642 |
| Bridgebio Pharma, Inc. | 20 | $20,540 |
| AstraZeneca | 33 | $15,585 |
| E.r. Squibb & Sons, L.L.C. | 37 | $15,064 |
| Boston Scientific | 93 | $7,744 |
| Medtronic(2 entities) | 52 | $7,540 |
| Abiomed | 5 | $1,351 |
| Abbott | 23 | $703 |
| Shockwave Medical, Inc | 20 | $466 |
| Amgen | 18 | $292 |
| Inari Medical, Inc. | 4 | $175 |
| Novartis | 8 | $104 |
| United Therapeutics Corporation | 4 | $94 |
| Angiodynamics, Inc. | 2 | $60 |
| Lemaitre Vascular, Inc. | 2 | $55 |
| Stryker | 2 | $52 |
| Merck | 3 | $46 |
| Cardiovascular Systems Inc. | 4 | $45 |
| Terumo Medical Corporation | 2 | $30 |
| Biotronik Inc. | 1 | $30 |
| W. L. Gore & Associates, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Biosense Webster, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Cook Medical LLC | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$78,568
- OPSUMIT$78,568
- JARDIANCE$49,216
- AMVUTTRA$39,052
- XARELTO$39,016
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$36,958
- VYNDAQEL$30,729
- Attruby$20,328
- FARXIGA$10,658
- CAMZYOS$9,527
- VYNDAMAX$8,322
- ROTAPRO$5,625
- WAINUA$4,550
- COREVALVE EVOLUT R$3,724
- Impella$1,244
- Watchman$1,153
- Micra$750
- Edwards SAPIEN 3 Transcatheter Heart Valve$625
- Xience V coronary stent system$133
- SAPIEN 3 Ultra RESILIA$131
How this compares
Too few interventional cardiology providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 23 | $846,265 |
| OpsumitMacitentan | 43 | $630,394 |
| EliquisApixaban | 462 | $399,601 |
| Orenitram ErTreprostinil Diolamine | 12 | $308,977 |
| JardianceEmpagliflozin | 168 | $153,243 |
| XareltoRivaroxaban | 162 | $147,481 |
| MounjaroTirzepatide | 97 | $103,627 |
| EntrestoSacubitril/Valsartan | 83 | $88,738 |
| FarxigaDapagliflozin Propanediol | 96 | $54,701 |
| Repatha SureclickEvolocumab | 65 | $40,060 |
| Praluent PenAlirocumab | 36 | $21,032 |
| BrilintaTicagrelor | 42 | $16,770 |
| Metoprolol Succinate | 808 | $14,875 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $14,813 |
| Repatha SyringeEvolocumab | 19 | $13,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $88,200 | $1,245,866485 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $80,971 | $630,39443 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $29,328 | $168,057180 claims |
| Johnson & JohnsonXarelto | $39,601 | $147,481162 claims |
| Lilly USA, LLCMounjaro | $20,642 | $103,62797 claims |
| NovartisEntresto | $104 | $88,73883 claims |
| AstraZenecaFarxiga, Brilinta | $15,585 | $71,471138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Bismarck
- Hai XuBismarck$25K
- Jared SteinbergerBismarck$9K
- Camelia IlieBismarck$1K
- John HoytBismarck$1K
- Boban MathewBismarck$124
- Robert OatfieldBismarck$45
- Yassar AlmanaseerFargo$216K
- Alok SauravFargo$10K
- Yara Letitia CameronGrand Forks$8K
- Puneet SharmaFargo$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.